Theratechnologies Inc. (NASDAQ:THTX) Sees Large Decline in Short Interest

Theratechnologies Inc. (NASDAQ:THTX) saw a large decline in short interest in January. As of January 31st, there was short interest totalling 10,200 shares, a decline of 73.4% from the January 15th total of 38,400 shares. Approximately 0.1% of the shares of the stock are sold short. Based on an average daily trading volume, of 103,600 shares, the short-interest ratio is presently 0.1 days.

Institutional Investors Weigh In On Theratechnologies

Large investors have recently added to or reduced their stakes in the stock. Cyndeo Wealth Partners LLC grew its position in Theratechnologies by 26.1% during the third quarter. Cyndeo Wealth Partners LLC now owns 131,311 shares of the company’s stock worth $163,000 after buying an additional 27,191 shares in the last quarter. National Bank of Canada FI lifted its position in shares of Theratechnologies by 29.4% in the 3rd quarter. National Bank of Canada FI now owns 186,815 shares of the company’s stock worth $232,000 after acquiring an additional 42,435 shares during the period. Wealthspire Advisors LLC grew its holdings in shares of Theratechnologies by 39.0% during the 4th quarter. Wealthspire Advisors LLC now owns 71,250 shares of the company’s stock worth $129,000 after purchasing an additional 20,000 shares in the last quarter. Raymond James Financial Inc. bought a new stake in shares of Theratechnologies during the fourth quarter valued at approximately $27,000. Finally, Harbour Investments Inc. raised its stake in shares of Theratechnologies by 20.0% in the fourth quarter. Harbour Investments Inc. now owns 87,772 shares of the company’s stock valued at $159,000 after purchasing an additional 14,655 shares in the last quarter.

Theratechnologies Stock Performance

Shares of NASDAQ THTX traded up $0.05 during mid-day trading on Wednesday, reaching $1.67. The company had a trading volume of 24,590 shares, compared to its average volume of 102,514. The stock has a fifty day moving average of $1.69 and a two-hundred day moving average of $1.42. Theratechnologies has a 12-month low of $1.08 and a 12-month high of $2.18. The company has a market capitalization of $76.79 million, a price-to-earnings ratio of -16.70 and a beta of 1.26.

Theratechnologies Company Profile

Theratechnologies Inc, a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen.